CRIS Current Research Information System

AUTERI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.128
EU - Europa 856
AS - Asia 553
AF - Africa 72
SA - Sud America 3
OC - Oceania 2
Totale 2.614
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.121
IT - Italia 229
SG - Singapore 180
SE - Svezia 159
CN - Cina 139
GB - Regno Unito 128
DE - Germania 126
VN - Vietnam 94
IN - India 88
IE - Irlanda 59
TG - Togo 35
RU - Federazione Russa 33
FR - Francia 30
CI - Costa d'Avorio 21
FI - Finlandia 20
JO - Giordania 16
BE - Belgio 14
BG - Bulgaria 14
CH - Svizzera 11
ID - Indonesia 11
NG - Nigeria 10
EE - Estonia 9
CA - Canada 7
HK - Hong Kong 7
ZA - Sudafrica 6
CZ - Repubblica Ceca 5
PL - Polonia 5
IR - Iran 4
TR - Turchia 4
UA - Ucraina 4
JP - Giappone 3
NL - Olanda 3
AT - Austria 2
BR - Brasile 2
ES - Italia 2
TW - Taiwan 2
AU - Australia 1
BD - Bangladesh 1
CL - Cile 1
CY - Cipro 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
Totale 2.614
Salva come PNG Salva come JPEG
Città #
Chandler 197
Singapore 166
Southend 110
Dong Ket 93
Ashburn 87
Santa Clara 74
Fairfield 69
Dublin 59
Bologna 52
Princeton 52
Boardman 41
Lomé 35
Hyderabad 34
Houston 33
Milan 32
Wilmington 29
Woodbridge 29
Seattle 28
Redmond 26
Cambridge 23
Ann Arbor 22
Abidjan 21
Turin 21
Bremen 18
Helsinki 17
Nanjing 17
Amman 16
New York 16
Berlin 14
Brussels 14
Sofia 14
Westminster 14
Los Angeles 12
Jakarta 11
Beijing 9
Boydton 9
Monheim 9
Bern 8
Abeokuta 7
Des Moines 7
Munich 7
Perugia 7
Medford 6
Modena 6
Saint Petersburg 6
Toronto 6
Brno 5
Casalecchio di Reno 5
Fremont 5
Guangzhou 5
Hong Kong 5
Norwalk 5
Shanghai 5
Falls Church 4
Florence 4
Leawood 4
Migliarino 4
Mountain View 4
Olalla 4
Paris 4
Phoenix 4
Qingdao 4
Redwood City 4
Rome 4
San Diego 4
Shenyang 4
Wenzhou 4
Abano Terme 3
Andover 3
Bari 3
Bühl 3
Cernusco sul Naviglio 3
Changchun 3
Changsha 3
Jinan 3
Lagos 3
Lappeenranta 3
Limidi 3
Nanchang 3
Pune 3
San Francisco 3
Shijiazhuang 3
Warsaw 3
Zhengzhou 3
Amsterdam 2
Central 2
Chicago 2
Dongguan 2
Fiesole 2
Forlì 2
Harbin 2
Hefei 2
Hounslow 2
Imola 2
Jinhua 2
Kuban 2
Langfang 2
Linyi 2
Madrid 2
Mannheim 2
Totale 1.757
Salva come PNG Salva come JPEG
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 145
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 145
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 145
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 140
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 137
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 137
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 133
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 121
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 115
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 115
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 100
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 93
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 91
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 85
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 79
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 69
null 68
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 68
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 66
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 64
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 64
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 62
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 55
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 46
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 43
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 38
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 37
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 33
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 26
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 26
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 25
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 24
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 21
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 20
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 19
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 19
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 19
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 18
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 16
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 15
Liver and spleen shear-wave elastography in the diagnosis and severity staging of myeloproliferative diseases and myelofibrosis 6
Totale 2.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.067
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020153 0 0 0 0 0 19 25 38 27 21 17 6
2020/2021295 37 14 8 2 2 17 7 23 50 3 8 124
2021/2022546 8 17 24 51 32 22 11 49 19 53 155 105
2022/2023760 56 100 45 104 62 78 15 46 137 28 57 32
2023/2024316 16 49 23 32 20 45 2 30 13 30 31 25
2024/2025525 90 95 89 92 118 41 0 0 0 0 0 0
Totale 2.748